pre-IPO PHARMA

COMPANY OVERVIEW

Ascentage Pharma is a global, clinical-stage biopharmaceutical company, dedicated to the discovery and development of "first-in-class" and "best-in-class" small-molecule targeted therapeutics for addressing unmet medical needs in cancers, Hepatitis B and age-related diseases.


LOCATION

  • Rockville, MD, USA
  • Suzhou, Jiangsu, China
  • Taizhou City, Jiangsu, China
  • Shanghai, , China
  • Beijing, , China
  • Guangzhou, , China

  • THERAPEUTIC AREAS

  • Aging
  • Infectious Disease
  • Oncology
  • Ophthalmology

  • WEBSITE

    https://www.ascentagepharma.com/


    CAREER WEBSITE

    https://www.ascentagepharma.com/recruit.html


    SOCIAL MEDIA


    INVESTORS

    arrowmark-partners bioventures-capital ccb-international cts-capital efung-capital future-industry-investment-fund grains-valley-venture-capital hdy-international-investment hidragon-capital kip-capital oriza-seed-venture-capital shiyu-capital teng-yue-partners yuanming-prudence-fund


    PRESS RELEASES


    Nov 4, 2019

    Ascentage Pharma and Henlius Form a Combination Therapy Strategic Collaboration


    Jul 21, 2019

    Ascentage Pharma to Initiate Phase Ib Study of HQP1351 in Tyrosine Kinase Inhibitors -resistant Chronic Myeloid Leukemia Patients in the US


    Jul 14, 2019

    Ascentage Pharma announces first patient dosed in Phase I clinical trial of APG-2575 in China as the first China-made Bcl-2 Inhibitor


    Jun 3, 2019

    Ascentage Pharma presents new clinical data of apoptosis-targeted drug candidates APG-115 and APG-1387 at 2019 ASCO


    May 22, 2019

    Ascentage Pharma to Present New Data at 2019 ASCO Annual Meeting from Clinical Trials of MDM2-p53 Antagonist and IAP Inhibitor in Cancers


    For More Press Releases


    Google Analytics Alternative